Source: British journal of cancer [Br J Cancer] 2012 Jun 05; Vol. 106 (12), pp. 1945-52. Date of Electronic Publication: 2012 May 15.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib.

Authors : Pantaleo MA; Department of Hematology and Oncological Sciences L&A Seràgnoli, S, Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. ; Mandrioli A

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*adverse effects ; Benzenesulfonates/Benzenesulfonates/Benzenesulfonates/*adverse effects ; Carcinoma, Renal Cell/Carcinoma, Renal Cell/Carcinoma, Renal Cell/*complications

Source: BMC cancer [BMC Cancer] 2012 Jun 11; Vol. 12, pp. 231. Date of Electronic Publication: 2012 Jun 11.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.

Authors : Hiles JJ; School of Pharmacy, University of Wisconsin, Madison, WI 53705, USA.; Kolesar JM

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; Benzenesulfonates/Benzenesulfonates/Benzenesulfonates/*therapeutic use ; Carcinoma, Renal Cell/Carcinoma, Renal Cell/Carcinoma, Renal Cell/*drug therapy

Source: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists [Am J Health Syst Pharm] 2008 Jan 15; Vol. 65 (2), pp. 123-31.Publisher: Oxford University Press Country of Publication: England NLM ID: 9503023 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib.

Authors : Di Fiore F; Digestive Oncology Unit, Department of Gastroenterology, Rouen University Hospital, 1 rue de Germont, Rouen Cedex, France.; Rigal O

Source: British journal of cancer [Br J Cancer] 2011 Dec 06; Vol. 105 (12), pp. 1811-3. Date of Electronic Publication: 2011 Nov 17.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial.

Authors : Procopio G; Department of Medical Oncology, Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian, Milan 1-20133, Italy. ; Verzoni E

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Benzenesulfonates/Benzenesulfonates/Benzenesulfonates/*administration & dosage ; Carcinoma, Renal Cell/Carcinoma, Renal Cell/Carcinoma, Renal Cell/*drug therapy

Source: British journal of cancer [Br J Cancer] 2011 Apr 12; Vol. 104 (8), pp. 1256-61. Date of Electronic Publication: 2011 Mar 29.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model.

Authors : Yuen JS; Department of Urology, Singapore General Hospital, Singapore.; Sim MY

Subjects: Benzenesulfonates/Benzenesulfonates/Benzenesulfonates/*therapeutic use ; Carcinoma, Renal Cell/Carcinoma, Renal Cell/Carcinoma, Renal Cell/*drug therapy ; Kidney Neoplasms/Kidney Neoplasms/Kidney Neoplasms/*drug therapy

Source: British journal of cancer [Br J Cancer] 2011 Mar 15; Vol. 104 (6), pp. 941-7.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print Cited Medium:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation.

Authors : Miyake H; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. ; Kurahashi T

Subjects: Quality of Life*; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; Benzenesulfonates/Benzenesulfonates/Benzenesulfonates/*therapeutic use

Source: BJU international [BJU Int] 2010 Dec; Vol. 106 (11), pp. 1643-7.Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print Cited Medium: Internet ISSN: 1464-410X

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.

Authors : Larkin JM; Department of Renal Oncology, The Royal Marsden Hospital NHS Foundation Trust, Fulham Road, London, SW36JJ, UK. ; Ferguson TR

Subjects: Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Benzenesulfonates/Benzenesulfonates/Benzenesulfonates/*administration & dosage

Source: British journal of cancer [Br J Cancer] 2010 Oct 12; Vol. 103 (8), pp. 1149-53. Date of Electronic Publication: 2010 Sep 14.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma.

Authors : Hou MM; Division of Haematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan.; Hsieh JJ

Subjects: Chromosomes, Human, X* ; Translocation, Genetic*; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use

Source: Clinical drug investigation [Clin Drug Investig] 2010; Vol. 30 (11), pp. 799-804.Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9504817 Publication Model: Print Cited Medium: Print ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.

Authors : Alfaro C; Gene Therapy and Hepatology Division, CIMA, Universidad de Navarra, Pamplona, Spain.; Suarez N

Subjects: Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*pharmacology ; Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*pharmacology ; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacology

Source: British journal of cancer [Br J Cancer] 2009 Apr 07; Vol. 100 (7), pp. 1111-9. Date of Electronic Publication: 2009 Mar 10.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.

Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib.

Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.

Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib.

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial.

Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model.

Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation.

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.

Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma.

Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.

اتصل بنا

اتبع